Brief: Rhythm Pharmaceuticals Receives Positive CHMP Opinion For Imcivree For The Treatment Of Obesity And Control Of Hunger
28/06/2024 13:41
June 28 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR
▼IMCIVREE® (SETMELANOTIDE) FOR THE TREATMENT OF OBESITY AND
CONTROL OF HUNGER IN PATIENTS BETWEEN 2 AND 6 YEARS OLD WITH
BARDET BIEDL SYNDROME OR POMC, PCSK1, OR LEPR DEFICIENCY
* RHYTHM PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION
ANTICIPATED IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNXc852l6
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand